Videos
Second-Line Therapy in Extranodal Marginal Zone Lymphoma
Perspective on Treating Advanced Marginal Zone Lymphoma
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Lung Cancer
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ozekibart in Unresectable or Metastatic Chondrosarcoma
2
Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma
3
PTCy Fails to Translate GVHD Reduction to Survival Advantage Vs ATG
4
FDA Approves Adjuvant Belzutifan Plus Pembro for Kidney Cancer
5